Abstract
Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel. This new approach requires major funding and human investments. Among the most widely studied agents for the chemoprevention of colorectal cancer, aspirin, the NSAIDs and COX-2 inhibitors seem to be the most promising. A large number of observational epidemiological studies show that regular use of aspirin and other NSAIDs is associated with a reduction in the risk of developing both colorectal adenomas and cancer. In addition, the prodrug sulindac reduces the growth of existing polyps in familial adenomatous polyposis (FAP). However, the dose, duration of effect and length of protection seen after cessation remain to be fully established. Furthermore, in view of previous discrepancies between the results of observational studies and randomized control trials (RCTs), it is crucially important to investigate the effects of aspirin by RCTs. RCTs investigating the effect of chemopreventive agents on adenoma recurrence as an intermediate endpoint for colorectal cancer is a more feasible approach than RCTs to investigate the effect on the incidence if colorectal cancer per se. Four RCTs of the effect of aspirin on adenoma recurrence are available. Other trials are currently underway.
Keywords: chemoprevention, aspirin, cox, colorectal carcinoma
Current Topics in Medicinal Chemistry
Title: Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Volume: 5 Issue: 5
Author(s): R. Benamouzig, B. Uzzan, J. Little and S. Chaussade
Affiliation:
Keywords: chemoprevention, aspirin, cox, colorectal carcinoma
Abstract: Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel. This new approach requires major funding and human investments. Among the most widely studied agents for the chemoprevention of colorectal cancer, aspirin, the NSAIDs and COX-2 inhibitors seem to be the most promising. A large number of observational epidemiological studies show that regular use of aspirin and other NSAIDs is associated with a reduction in the risk of developing both colorectal adenomas and cancer. In addition, the prodrug sulindac reduces the growth of existing polyps in familial adenomatous polyposis (FAP). However, the dose, duration of effect and length of protection seen after cessation remain to be fully established. Furthermore, in view of previous discrepancies between the results of observational studies and randomized control trials (RCTs), it is crucially important to investigate the effects of aspirin by RCTs. RCTs investigating the effect of chemopreventive agents on adenoma recurrence as an intermediate endpoint for colorectal cancer is a more feasible approach than RCTs to investigate the effect on the incidence if colorectal cancer per se. Four RCTs of the effect of aspirin on adenoma recurrence are available. Other trials are currently underway.
Export Options
About this article
Cite this article as:
Benamouzig R., Uzzan B., Little J. and Chaussade S., Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer, Current Topics in Medicinal Chemistry 2005; 5 (5) . https://dx.doi.org/10.2174/1568026054201631
DOI https://dx.doi.org/10.2174/1568026054201631 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Counselling and Cognitive Behaviour Interventions Delivered to Reduce Psychological Morbidity and Improve Quality of Life in Gynaecological Cancer Patients: Recent Achievements
Current Women`s Health Reviews Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology Antioxidant Constituents from the Stem and Leaf of Helicteres hirsuta Loureiro
The Natural Products Journal Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Quinoline as a Privileged Scaffold in Cancer Drug Discovery
Current Medicinal Chemistry Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention
Current Cancer Drug Targets Pistachio Green Hull Extract Induces Apoptosis through Multiple Signaling Pathways by Causing Oxidative Stress on Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
Current Drug Targets The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets
Current Cancer Drug Targets Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Current Medicinal Chemistry Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design ADP-Ribosyltransferases and Poly ADP-Ribosylation
Current Protein & Peptide Science Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets